Bokf Na Sells 2,840 Shares of Thermo Fisher Scientific Inc. $TMO

Bokf Na trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,570 shares of the medical research company’s stock after selling 2,840 shares during the quarter. Bokf Na’s holdings in Thermo Fisher Scientific were worth $11,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. SevenBridge Financial Group LLC increased its position in shares of Thermo Fisher Scientific by 21.8% during the third quarter. SevenBridge Financial Group LLC now owns 6,034 shares of the medical research company’s stock worth $2,927,000 after buying an additional 1,079 shares during the period. SageView Advisory Group LLC boosted its position in Thermo Fisher Scientific by 8.7% during the third quarter. SageView Advisory Group LLC now owns 3,004 shares of the medical research company’s stock valued at $1,457,000 after acquiring an additional 241 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after acquiring an additional 62,790 shares during the period. Franklin Resources Inc. lifted its stake in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after purchasing an additional 1,028,125 shares during the period. Finally, Magnetar Financial LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $232,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TMO shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. UBS Group reaffirmed a “neutral” rating and set a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Barclays increased their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Finally, Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $475.78 on Friday. The company has a market cap of $176.74 billion, a P/E ratio of 26.82, a PEG ratio of 2.86 and a beta of 0.96. The company has a fifty day simple moving average of $560.39 and a 200 day simple moving average of $548.36. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned $6.10 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is presently 9.70%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.